Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR91 | A4D1P6 | 2/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 14/20 | 0.49 |
| ▸ | PHGDH | O43175 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20544741 | 0.90 | UTS2R (0.51) | UTS2RKDM4EGAA | |
| SCHEMBL21979517 | 0.86 | KDM4E (0.47) | UTS2RPHGDHKDM4EGAA | |
| SCHEMBL21979535 | 0.86 | KDM4E (0.47) | UTS2RPHGDHKDM4EGAA | |
| SCHEMBL8514238 | 0.86 | KDM4E (0.47) | UTS2RPHGDHKDM4EGAA | |
| SCHEMBL20544752 | 0.85 | UTS2R (0.48) | UTS2RKDM4EGAA | |
| SCHEMBL3886204 | 0.84 | ROCK1 (0.56) | PHGDHKDM4EGAA | |
| SCHEMBL1120036 | 0.84 | ROCK1 (0.56) | PHGDHKDM4EGAA | |
| SCHEMBL22691123 | 0.83 | CYP1A2 (0.44) | — | |
| SCHEMBL21962635 | 0.83 | CYP1A2 (0.44) | — | |
| SCHEMBL4075272 | 0.83 | CNR2 (0.43) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180312516-A1 | Protein Kinase B Inhibitors | ASTRAZENECA AB (SE) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312516-A1 | Protein Kinase B Inhibitors | PRKAR2B, PRKCB, AKT1 | WDR91 1795/4885UTS2R 3101/4885PHGDH 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.